Abstract
Heart Failure (CHF) is a very important public health problem in the world and certainly one of the most common debilitating diseases and cause of mortality. Current knowledge underlines that incidence rates are also influenced by the coexisting pathologic conditions that accelerate the development of disease or increase its severity. Important scientific evidence is emerging to demonstrate a strong correlation between HF and the metabolic syndrome (MetS). Hypolipemia- inducing medication offers the opportunity to discuss the possible existence of pharmacological substances that in addition to their specific targets have several demonstrated pleiotropic effects that could be beneficial in HF. Although several trials investigated statins treatment effects on HF in general, some evidence exists about the role that these drugs can have in the progression of the disease in the specific category of HF patients affected by MetS. In this review the possible positive effects of the statins treatment in this specific subset of patients are discussed.
Keywords: Congestive heart failure, metabolic syndrome, statins
Current Pharmaceutical Design
Title: The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Volume: 14 Issue: 25
Author(s): Giovanni Fazio, Gisella Rita Amoroso, Giuseppe Barbaro, Giuseppina Novo and Salvatore Novo
Affiliation:
Keywords: Congestive heart failure, metabolic syndrome, statins
Abstract: Heart Failure (CHF) is a very important public health problem in the world and certainly one of the most common debilitating diseases and cause of mortality. Current knowledge underlines that incidence rates are also influenced by the coexisting pathologic conditions that accelerate the development of disease or increase its severity. Important scientific evidence is emerging to demonstrate a strong correlation between HF and the metabolic syndrome (MetS). Hypolipemia- inducing medication offers the opportunity to discuss the possible existence of pharmacological substances that in addition to their specific targets have several demonstrated pleiotropic effects that could be beneficial in HF. Although several trials investigated statins treatment effects on HF in general, some evidence exists about the role that these drugs can have in the progression of the disease in the specific category of HF patients affected by MetS. In this review the possible positive effects of the statins treatment in this specific subset of patients are discussed.
Export Options
About this article
Cite this article as:
Fazio Giovanni, Amoroso Rita Gisella, Barbaro Giuseppe, Novo Giuseppina and Novo Salvatore, The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome, Current Pharmaceutical Design 2008; 14 (25) . https://dx.doi.org/10.2174/138161208786071218
DOI https://dx.doi.org/10.2174/138161208786071218 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Endothelial Function and Pathogenesis of Endothelial Dysfunction
Current Immunology Reviews (Discontinued) Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Current Pharmaceutical Design Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design Independent Relationship between Serum Osteocalcin and Uric Acid in a Cohort of Apparently Healthy Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Perspective of Molecular Hydrogen in the Treatment of Sepsis
Current Pharmaceutical Design Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: The Coronary Collateral Circulation – Past, Present and Future)
Current Cardiology Reviews PREFACE [Hot topic: Nuclear Hormone Receptor Modulators as Targets for Drug Discovery (Guest Editor: Timothy Grese)]
Current Topics in Medicinal Chemistry The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma
Current Respiratory Medicine Reviews Multiple Pharmacological Properties of a Novel Parthenin Analog P16 as Evident by its Cytostatic and Antiangiogenic Potential Against Pancreatic Adenocarcinoma PANC -1 Cells
Anti-Cancer Agents in Medicinal Chemistry Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Physical and Mental Functions of Cardiovascular Diseased Patients Decrease During the State of Emergency Initiated by the COVID-19 Pandemic in Japan
Reviews on Recent Clinical Trials MicroRNA in Aging: From Discovery to Biology
Current Genomics Breast Cancer Biomarkers: Risk Assessment, Diagnosis, Prognosis, Prediction of Treatment Efficacy and Toxicity, and Recurrence
Current Pharmaceutical Design The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Acute Coronary Syndromes in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Role of Dietary Xenobiotics-Gene Interactions in Carcinogenesis: Protective Effects of Nutritional Factors
Current Nutrition & Food Science The Roles of Cytochrome P450 in Ischemic Heart Disease
Current Drug Metabolism